-((S)-1-(4-(1-methyl-2-oxo-1,2-dihydropyridin-4-yl)phenyl)ethyl)-6-phenyl-1,3-oxazinan-2-one (1) and (4aR,9aS)-1-(1H-benzo[d]midazole-5-carbonyl)-2,3,4,4a,9,9a-hexahydro-1-H-indeno[2,1-b]pyridine-6-carbonitrile hydrochloride (2) are potent and selective inhibitor of 11β-hydroxysteroid dehydrogenase type 1 enzyme. These 2 drug candidates developed for the treatment of type-2 diabetes were prepared labeled
(S)-6-(2-Hydroxy-2-methylpropyl)-3-((S)-1-(4-(1-methyl-2-oxo-1,2-dihydropyridin-4-yl)phenyl)ethyl )-6-苯基-1,3-oxazinan-2-one (1) 和 (4aR,9aS)-1-(1H-benzo[d]midazole-5-carbonyl)-2,
3,4,4a,9 ,9a-hexahydro-1-H-indeno[2,1-b]pyridine-6-carbonitrile hydrochloride (2) 是 11β-羟基类
固醇脱氢酶 1 型酶的有效选择性
抑制剂。为治疗 2 型糖尿病而开发的这 2 种候选药物制备有碳 13 和碳 14 标记,以进行药物代谢、药代动力学、
生物分析和其他研究。在碳 13 合成中,
苯甲酸 13 C6 酸分 7 个步骤以 16% 的总产率转化为 [13 C6]-(1)。
苯胺-13